Michael Kalos, Ph.D., is an Adjunct Associate Professor of Pathology and Laboratory Medicine at the University of Pennsylvania where he is also a Director for the Translational and Correlative Studies Laboratory.
Dr. Kalos has been studying the complexity of lymphocytes and T cell receptors for more than 15 years.
Discussing his work using the immunoSEQ profiling assay, Dr. Kalos explains, “immunoSEQ offers a truly revolutionary approach to viewing T and B cells and their diversity. It’s given me unprecedented detailed information in a very short period of time, and enabled me to track the state of T and B cells in our ongoing immunotherapy clinical trials.”
Dr. Kalos, for example, uses the profiling service to obtain quantifiable information about the diversity of B cells that survive in patients after an infusion of T lymphocytes that target malignant B cells. The data was able to tell him that the treatments had eliminated all detectable B cells in certain patients.
“I’m very impressed with immunoSEQ’s ability to provide such a granular view of T cells and B cells present in samples,” he continues. “This service has fundamentally changed how my lab does analysis of our clinical trials.”
By using immunoSEQ’s immune repertoire profiling data side-by-side alongside more traditional technologies such as flow-based assays, Dr.Kalos is able to present a more comprehensive and multi-faceted picture of the underlying adaptive immune system dynamics.
Thank you for writing Researcher Spotlight: Dr.
Michael Kalos – ImmunoSEQ by Adaptive Biotechnologies,
I actually was researching for something very similar and was happy
to find the information as a result of this particular post.